evidence: This is to be noted in the current pandemic situation that the US Food and Drug Administration (USFDA) approved the use of the Pfizer-BioNTech (BNT162b2 vaccine) and Moderna vaccine (mRNA-1273 vaccine), both of which are the mRNA vaccines (whereby the SARS-CoV-2 spike glycoprotein (S) antigen is encoded by the mRNA and then devised in the lipid nanoparticles or the LNPs) with more than 90% effectiveness in candidates 16 years of age or older with 2 days within 21 days [13,14,15]. Descriptively, the mRNA-1273 vaccine (whereby the mRNA encoding the S-2P antigen, containing the SARS-CoV-2 glycoprotein attached to a transmembrane anchor, and an intact S1–S2 cleavage site, and is enclosed by a 4 subunit lipid nanoparticle) which has undergone the first-in-human dose-dependent (25 or 30, 100, and 250 μg), open-label phase II clinical trial NCT04283461 (with the fast-track approval from the USFDA as stated above) successfully detected the elevated neutralizing antibody titers and the required T cell responses [3, 6, 11, 13]. A unique characteristic of this vaccine is that this one is free from any preservative [12].